RightFit
RecruitingNot applicable

Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE Trial

UPRISE (Urine Prostate Screening Integrated With MRI for Prostate Cancer Early Detection)

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
50 Years to 75 Years
Sex
Male only
Healthy volunteers
Accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

  • Procedures mentioned: MRI scans, Biopsies

Only what the study's summary and detailed description on ClinicalTrials.gov say. Time periods may describe the whole study or a part of it — ask the study team what applies to you.

Show the study's own words
  • "This clinical trial tests how well a urine prostate cancer screening test, My Prostate Score 2 (MPS2), integrated with magnetic resonance imaging (MRI) works for early detection of prostate cancer."
  • "Results may lead to paradigm shifts in early detection algorithms and reduce reliance on MRI and biopsy."
Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study tests how well a urine test called My Prostate Score 2 (MPS2), used with an MRI scan, finds prostate cancer early. MPS2 is an experimental test that looks for signs in urine, including genetic information, of cancer that may grow or spread quickly. The study is for men ages 50–75 who meet certain PSA blood test levels and other health rules.

This clinical trial tests how well a urine prostate cancer screening test, My Prostate Score 2 (MPS2), integrated with magnetic resonance imaging (MRI) works for early detection of prostate cancer. MPS2 is an investigational urine-based test designed to help identify the likelihood of having aggressive prostate cancer. MPS2 testing works by measuring specific early detection biomarkers that include genetic information. This next-generation test aims to address a major challenge in prostate cancer care-detecting only the cancers that truly need treatment. Results may lead to paradigm shifts in early detection algorithms and reduce reliance on MRI and biopsy.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Men ages 50–75.
  • PSA level of 3–20 ng/ml in the past 3 months. PSA is a protein measured in a blood test to check prostate health.
  • Your treating doctor says you can safely have all study procedures.
  • No prostate biopsy in the past 4 years. A biopsy removes a small tissue sample for testing.
  • No prostate MRI in the past 2 years. MRI uses magnets to make pictures inside the body.
  • Able to give written consent to join the study.

Who can't join

  • You have been diagnosed with prostate cancer before.
  • You cannot have an MRI, for example because of a pacemaker or fear of tight spaces.
  • You cannot have a prostate biopsy.
  • You have had hip replacement surgery, a metal hip replacement, or major surgery that placed metal in your pelvic bones.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * Males aged 50-75 * PSA 3-20 ng/ml within the previous 3 months * Fit to undergo all procedures listed in protocol per treating physician's discretion * No prostate biopsy in the past 4 years * No prostate MRI in the past 2 years * Able to provide written informed consent Exclusion Criteria: * Prior diagnosis of prostate cancer * Contraindication to MRI (e.g. claustrophobia, pacemaker) * Contraindication to prostate biopsy * Previous hip replacement surgery, metallic hip replacement or extensive pelvic orthopaedic metal work

Study sites (1)

MI